Categories
Patents Q&A

What Are Claims in a Patent?

Patents and patent applications typically have one or more “claims”. But what are claims? What is the significance of claims in patent law? This article offers a brief explanation of what they are and why they matter. It also explains some common misunderstandings and misconceptions about patent claims that can lead to great confusion.

Purpose of Claims

Patents provide exclusive rights in the form of a limited monopoly to an invention. Claims define the scope of exclusive legal rights in a granted patent or, in the case of a patent application, the scope of exclusive rights being sought. In other words, when thinking of patents as being premised on a quid pro quo, claims define the boundaries of the exclusive rights granted by a government to the patentee in exchange for disclosing an invention.

A common way to explain patent rights is to analogize them to real property (that is, land ownership). The claims are what establish the boundaries or metes-and-bounds of legal rights to a given patented invention. So claims are a bit like lot lines that establish the perimeter of a plot of land. Anything falling within the scope of a claim is protected. Just like the area within lot line boundaries belongs to the landowner.

Consider this simple guideline for granted patents: anything claimed is patented, and anything not claimed is not patented. In that sense, claims put others on notice of the scope of exclusive rights held by a patentee. And, when a new patent application is filed, the claims are the main focus of examination to determine if the invention (as claimed) is patentable. A patent is only being sought for what the claims of a given application recite.

Under U.S. patent law, claims are considered a part of the “specification” of a patent application. The basic requirements for claims are set forth in Section 112 of those patent statutes:

“The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.”

35 U.S.C. § 112(b)

When the U.S. patent laws set out what constitutes infringement of a “patented invention” (35 U.S.C. § 271). This is a reference to the claims. That is because the claims are what define the scope of the patented invention.

However, patent laws may differ between countries. For instance, the USA follows what is called peripheral claiming. Peripheral claims set forth the outermost boundaries of the exclusive rights with reasonable clarity, and anything outside the claims is generally not protected (with a rare exception under the doctrine of equivalents). But some other countries follow central claiming instead. Under central claiming regimes, the claims set out a basic inventive concept and the exclusive patent rights encompass an area that might extend beyond the literal scope of the claim language based upon the inventor(s)’s contribution over the prior art (as later determined by a court). Peripheral claiming makes the scope of rights more certain prior to an infringement lawsuit.

Content

What claims say and how they say it varies. They are unique to each application or patent. They are also written by patent applications, who have considerable discretion over what they recite and how they are formulated. Claims are meant to define inventions, so they necessarily vary to reflect the particular subject matter of a given invention. But any given claim might define an invention broadly or narrowly in scope, relatively speaking.

In order for a patent application to be found patentable, its claims have to meet the requirements for patentability. Among other things, this means that the claims must distinguish the invention over the prior art. Accordingly, claims of a given application may try to distinguish the prior art by reciting elements (also called limitations) that go beyond what was already known.

Claims can be—and often are—amended, and may between an original application, a pre-grant published application, and/or a later-granted patent. Claims might also be canceled/deleted or new claims added during examination (which is also called “prosecution”). There are even procedures to amend or correct claims after a patent has issued. This means that the substantive content of the claims can change over time. Sometimes this means that a given claim is narrowed by amendment to establish patentability. This can give rise to prosecution history estoppel.

The interpretation or construction of terms in a patent claim is very important. For instance, certain terms of art may have special legal or technical meaning. The way claims are interpreted can vary greatly between different jurisdictions.

Format

The format in which claims are written follow some general guidelines, even if their substantive content varies. For instance, they always appear at the very end of U.S. patents. They are each written as a single sentence. Parts of a claim may start on separate lines with special indenting to highlight distinct clauses. Although any given clause might contain multiple discrete limitations or elements. It is common for claims to use words like “wherein” and “comprising” that are not often used in everyday speech.

Means-plus-function (or step-plus-function) limitations are also a special type of claiming format permitted in the USA (35 U.S.C. § 112(f)). These limitations are interpreted to cover corresponding structures, materials, or acts disclosed elsewhere in the patent or application (and their known equivalents). Understanding when means-plus-function claiming is invoked or applies, and how to properly interpret the scope of that limitation, is sometimes difficult. But one rule is clear. There can be no “single means” claims, because a claim that contains only a single limitation in means-plus-function format would be an impermissible central claim rather than a peripheral claim.

A patent may have only one, a few, or very many claims. Typically, each claim is separately numbered. Some claims may refer back to prior claims by number. However, U.S. design patents have only a single unnumbered claim. U.S. plant patents also have only a single claim but it is numbered. Regardless of how many are present, each claim is generally considered separately. In this respect, claim numbering helps indicate how many different definitions of a given invention must be considered when evaluating either patentability/validity or infringement.

Types of Claims

Independent Claims vs. Dependent Claims

Claims can be either independent or dependent (35 U.S.C. § 112(c)). An independent claim stands on its own. In contrast, a dependent claim refers back to a prior claim (by number) and incorporates the limitations of all base claims (35 U.S.C. § 112(d)). The status of a given claim as either independent or dependent can have important legal significance for patentability/validity and other analyses.

The following is an example of a set of four claims in which claims 1 and 4 are independent claims and claims 2 and 3 are dependent claims:

1. An apparatus comprising an element A, an element B, and an element C.
2. The apparatus of claim 1, wherein the element A and the element B are each made of metal.
3. The apparatus of claim 2, wherein the element A is welded to the element B.
4. A method comprising step X, step Y, and step Z.

In the example above, claim 2 depends from claim 1. Because of that dependency, claim 2 incorporates all of the elements or limitations of independent base claim 1 and further adds an additional limitation. Claim 3 depends from claim 2, which in turn depends from claim 1. This means claim 3 incorporates all of the limitations of both base claims 1 and 2 and further adds an additional limitation. Claim 4 is another independent claim, which stands on its own. The limitations of claims 1-3 are not incorporated into claim 4.

Claim 1 of any patent or patent application is always an independent claim, because there is no prior claim to refer back to. Any claims that follow claim 1 might also be independent, or might be dependent. This depends on how they are written. Patentees have considerable latitude over how many claims and what types of claims are present. Although dependent claims are not permitted in U.S. design or plant patents.

When analyzing patents and patent applications, independent claims usually always require consideration, while dependent claims might not in some situations. For example, when assessing potential infringement, a dependent claim can only be infringed if its independent base claim is also infringed. But an independent claim might be infringed even if no dependent claim is infringed. So, in many contexts, dependent claims can be thought of as reciting optional features. Yet dependent claims might still be important. Validity and patentability are assessed on a claim-by-claim basis, so while an independent claim might be unpatentable (or invalid), dependent claims depending from it might still be patentable (or valid).

Multiple Dependent Claims

Multiple dependent claims are also possible (35 U.S.C. § 112(e)). A multiple dependent claim refers back to multiple prior claims in the alternative. Examples of multiple dependent claim references are “the method of any preceding claim” or “the apparatus of claim 1 or 2” or “the system of any of claims 2, 4, and 8.” The easiest way to think about multiple dependent claims is that they always present a single claim that is equivalent to having a number of separate dependent claims that each depend from different base claims.

Omnibus Claims

An omnibus claim makes a general incorporation into a claim of some other disclosure, without specifically defining the invention or even a central inventive concept. An example is “The apparatus substantially as shown and described.” Omnibus claims are permitted in some jurisdictions, but not in U.S. utility patents. Except U.S. design patents always have only a single omnibus claim reciting the design “as shown and described” (37 C.F.R. § 1.153(a)). And U.S. plant patents always have a single claim in omnibus format that states “as described and illustrated” (37 C.F.R. § 1.164)—although plant patents cover only asexual reproduction of the patented plant, through grafting, cuttings, etc., which distinguishes their claims from true omnibus claims in terms of their effect.

Other Types

There are a number of other names given to certain types of claims, often more informally. For instance, Jepson claims specifically identify the point of novelty (in a manner called two-part form in many jurisdictions), combination claims recite a particular combination of components, a Beauregard claim recites a computer-readable medium on which computer program instructions are encoded, product-by-process claims recite an apparatus in terms of how it is made, etc.

Difference Between Claims and Other Disclosures

One of the most important things to understand is that the claims of a given patent—and not other parts of a patent like the detailed description or drawings— define exclusive rights to a patented invention. As already mentioned, what is claimed is patented and what is not claimed is not patented. This means it is possible to have unclaimed disclosures in a given patent. For instance, a patent might include a drawing illustrating a prior art device but not claim it. In other cases, a patent might claim only one or a few particular embodiments or “species” of an invention and not a generic invention (or entire “genus”).

When trying to understand if their is risk of infringing someone else’s patent, a mistake frequently made by people unfamiliar with patent law is to look at the drawings or some other text in the specification (like the detailed description section) and assume that any and all such disclosures are “patented”. That is incorrect. Only the claims define the patented invention. There are many reasons why there might be unclaimed subject mater disclosed in a patent—including a patent office determining that some aspects were or are not patentable. But often those reasons are unimportant. It is the claims, as properly construed, that define the scope of the patentee’s exclusive rights.

In contrast, if a given prior art patent or published patent application is cited as prior art, it usually makes no difference whether the relevant prior art teachings were claimed or not. Most of the time the claims are irrelevant to the value of a given reference as prior art—with some exceptions for situations like double patenting.

Photo of Austen Zuege

Austen Zuege is an attorney at law and registered U.S. patent attorney in Minneapolis whose practice encompasses patents, trademarks, copyrights, domain name cybersquatting, IP agreements and licensing, freedom-to-operate studies, client counseling, and IP litigation. If you have patent, trademark, or other IP issues, he can help.

Categories
Patents Q&A

How Do AFCP 2.0 Requests Work?

The U.S. Patent & Trademark Office (USPTO) has a patent-related pilot program called the After Final Consideration Pilot 2.0 or “AFCP 2.0”. How does this AFCP program work, and how can these requests be made? This article addresses those basic questions.

Basic Contours of the Pilot Program

AFCP 2.0 is meant to foster compact prosecution. It aims to reduce the number of requests for continued examination (RCEs) and to foster examiner-applicant collaboration. To do that, the program authorizes additional time for examiners to search and/or consider qualifying responses after a final rejection. The program also involves an examiner-initiated interview if the response does not result in allowance. Some information about the program is available from the USPTO online, including some limited answers to frequently asked questions (FAQs).

The crux of the AFCP 2.0 program is that it expands the amount of time examiners have to act on a given after-final amendment to a pending patent application. Understanding how time constraints work during examination and how AFCP alters them is therefore important in order to grasp how the program may or may not benefit an applicant. However, the USPTO does not widely publicize how much time examiners have to begin with to consider an after-final response, or how much additional time is provided. These time constraint matters are taken up below.

Currently, participation in the program is free, but the USPTO has proposed an official fee requirement intended to go into effect in 2025.

As a pilot program, AFCP is implemented yearly. But it has been renewed every year since its inception.

Examination Time Constraints

The first point to understand is the “count” system that governs USPTO examiners’ work. Essentially, it is tied to a collective bargaining agreement with the unionized examination corps. This count system is complex. But the most important feature is that it basically allocates a fixed amount of time for examiners to spend on a patent application, based upon pre-determined levels of technological complexity and the particular assigned examiner’s seniority status. This averages only about nineteen or twenty hours per application, but can be much less or much more than that for a given application. For instance, some examples of these time variations by technology area are given here and here. And an explanation of examiner seniority-based variations is found here.

Under normal circumstances (not under the AFCP program), an examiner may spend only about 30 minutes considering an after-final response.

The USPTO’s Federal Register notice and web page about AFCP mentions only “a set amount of time”, without specifying the length of additional time allocated. But relevant information is available elsewhere. In actuality, the additional examination time allocated for each granted AFCP 2.0 request is 2-3 hours. For utility and plant applications, there is an additional two hours of substantive search/consideration time plus one extra hour of time for an interview (which can be reallocated for substantive examination potentially, in the absence of an interview). For design applications, there is only one additional hour of substantive examination time, plus the same one hour of additional interview time (which can also be reallocated in the absence of an interview).

Eligibility Requirements

There are a number of requirements to for an after-final amendment to qualify for this pilot program. The most important ones are:

  • There is an outstanding final rejection of at least one claim
  • An amendment is made to at least one independent claim that does not broaden the scope of that independent claim in any aspect
  • A certification and request (on USPTO form PTO/SB/434) is filed with the responsive amendment

The complete requirements can be found on the USPTO’s AFCP request form or via the USPTO’s program explanation web page.

Importantly, the required amendment to an independent claim does not have to be a narrowing amendment. It could merely be a clarification or correction of an error. Also, the program does not preclude a broadening amendment to another claim.

How to Make an AFCP Request

The key to making an AFCP request is to submit the required USPTO form along with an after-final amendment that meets the eligibility requirements discussed above. These requests must be filed electronically and not in hard copy by mail. The request form looks like this:

Image of main page of the USPTO's "Certification and Request for Consideration Under the After Final Consideration Pilot Program 2.0", form PTO/SB/434 (version 3-22)
USPTO AFCP 2.0 Certification and Request form PTO/SB/434 (version 3-22 shown)

Currently, there is no fee for this request. However, the USPTO has proposed an official fee requirement intended to go into effect in 2025.

The certification on the form indicates that the applicant is willing and able to conduct an interview. Nonetheless, substantive program materials contemplate that an applicant might later be unavailable or refuse an interview—contrary to what is stated at the end of section 8 of the USPTO’s certification and request form.

Is an AFCP Request Worthwhile?

Is it worthwhile, or a good idea, to make an AFCP request? Every case is different and there is no one correct approach. From an applicant’s perspective, an AFCP request is relatively easy to file. And the time needed for an interview may be short and not by itself a deterrent to making a request. So an AFCP request is often worth making if an independent claim is being amended. Whether it is desirable to amend a claim merely to qualify for AFCP 2.0 is another question entirely, and not something automatically recommended as a general matter (but possibly worthwhile in some circumstances).

This program tends to be most effective with relatively straightforward amendments. Or with amendments resulting from an examiner interview. Amendments implementing something essentially already suggested by the prosecution history tend to get a lot of benefit from it.

But the additional time allocated by an AFCP 2.0 request is not that large. That is particularly true if significant searching and consideration by the examiner is necessitated by a given response. Substantial, complex, or extensive amendments and/or arguments often require more examiner time to evaluate. These might not be resolved through the program. Applicants cannot expect miracles. All this is to say that after-final practice runs up against the count system and the time examiners are willing and able to allot to handling applicant responses. AFCP 2.0 may give examiners a little more time, but whether that additional time is enough time will vary widely on a case-by-case basis.

Photo of Austen Zuege

Austen Zuege is an attorney at law and registered U.S. patent attorney in Minneapolis whose practice encompasses patents, trademarks, copyrights, domain name cybersquatting, IP agreements and licensing, freedom-to-operate studies, client counseling, and IP litigation. If you have patent, trademark, or other IP issues, he can help.

Categories
Patents Q&A

What Is the Deadline to File a Continuing Patent Application?

A continuing patent application such as a divisional, continuation, or continuation-in-part (CIP) is possible in the USA. But what is the deadline to file one of these applications?

What Is a Continuing Patent Application?

A continuing patent application is one that claims priority to (or the domestic benefit of) a prior U.S. patent application or PCT international application that designated the USA. (See 35 U.S.C. §§ 120 and 121 and 37 C.F.R. § 1.53(b)). That means these are follow-on patent applications. They always relate back to one or more prior “parent” application(s). These can also be referred to as “child” applications in a patent “family”.

In other countries, the terminology for continuing applications may differ. For instance, many countries permit only subsequent “divisional” applications, and do not have different names for different types of continuing applications.

Deadline to file a Divisional, Continuation, or CIP Patent Application

Section 120 of the U.S. patent laws establishes that a continuing application (including divisionals, continuations, and CIPs) must be filed “before the patenting or abandonment of or termination of proceedings” of a parent application. In addition, USPTO regulations under 37 CFR § 1.78(d) state that a continuing application can be filed while the parent application is “copending”.

The Federal Circuit has ruled that so-called “same-day” continuing application filings are permitted, meaning a continuing application can be filed on the same day that a parent application issues as a patent. This confirmed longstanding U.S. Patent & Trademark Office (USPTO) practice, despite the statutory language literally saying “before” rather than “copending” or referring to the same day of patenting. Currently, this means that continuing applications can be filed up to and including the date that a parent application issues as a granted patent.

Another important aspect of the USPTO’s “copending” requirement is that the parent case cannot be abandoned. If the parent case will not issue, but an office action or the like is outstanding, then it is necessary to file the continuing application either (a) during the shortened statutory response period in the parent case or (b) after the shortened statutory period but before the maximum six-month statutory period along with the payment of monthly extension of time fees in the parent application. In other words, extension of time fees may be required in the parent case in order for the continuing application to be considered “copending”. This is referenced obliquely in MPEP § 710.02(e) and more clearly in old USPTO notices.

For continuing applications related to a prior PCT international application, such as a PCT “bypass” application in the U.S., the USPTO’s “copending” requirement means that the continuing application must be filed by the national phase entry deadline. In the U.S. this is 30 months from the earliest priority date.

The deadlines for continuing applications in other jurisdictions (often referred to only as divisionals) varies considerably. Deadlines for divisional or other continuing applications in foreign patent offices may arise much sooner than the deadlines under U.S. patent law and practice. For instance, Brazil requires divisional filing before a final office action or allowance is issued, which is a date that cannot be precisely determined in advance.

Best Practices

It is a best practice to file any continuing application as early as possible, and in the USA no later than with the payment of the issue fee or by the shortened statutory period deadline for a response in the parent case. While it may be possible to file a continuing application after such a date, problems and additional fees could arise.

For example, the Federal Circuit decision allowing continuing application filings on the same day as issuance of the parent is contrary to the literal language of the status, and might be overturned someday. There may also be filing system outages, illnesses or other complications that make a last-minute same-day filing difficult as a practical matter.

Also, the USPTO’s switch to “eGrant” electronic-only patents means that the delay between issue fee payment and subsequent issuance will become shorter than when hard copies were printed and mailed in the past. Indeed, on this point the USPTO has formally commented that reducing patent pendency is required by statute, while giving applicants time to file continuing applications is not, so “[a]pplicants should file their continuing applications as early as possible, preferably prior to payment of the issue fee to avoid any loss of rights.”

If an office action is outstanding in a parent case that will be abandoned, filing continuing applications early also avoids the need to pay an extension of time fee in the parent. The need to pay that extension of time fee in the parent might also be easily overlooked and missed, jeopardizing any resultant patent.

Lastly, delays in filing a continuing application may also delay examination and chip away at the available term for any resultant utility or plant patent issuing from a continuing application. (However, this point is not a concern for design patents, which have a fixed term from issuance).

Photo of Austen Zuege

Austen Zuege is an attorney at law and registered U.S. patent attorney in Minneapolis whose practice encompasses patents, trademarks, copyrights, domain name cybersquatting, IP agreements and licensing, freedom-to-operate studies, client counseling, and IP litigation. If you have patent, trademark, or other IP issues, he can help.

Categories
Patents Q&A

What Is a Published Patent Application?

People unfamiliar with patents and patent law are often confused about published patent applications. This article provides a brief overview of what a published patent application is and, importantly, how it differs from a granted patent.

Contents of a Published Application

Pre-grant publication means that patent applications that have not yet been fully examined are published while still pending. This gives the general public a view of the contents of the pending application. And even if no patent is ever granted, the contents of the published application are normally still made public (with some exceptions). Published patent applications can be relied upon as prior art against later applications. In the USA, only non-provisional utility and plant patent applications are subject to pre-grant publication. Pre-grant publication normally occurs after eighteen months have elapsed from the earliest priority date.

A published patent application—or patent application publication—will take a form determined the relevant jurisdiction. In the USA, for example, each application is specially formatted for pre-grant publication in a two-column format using paragraph numbers. This means the appearance of the published application will differ from what the applicant(s) originally filed.

Excerpt of the front page of United States Patent Application Publication Number US 2023/0000001 A1 to Weinan Wu for an "Assembled Garden Tool"
Example excerpt from front page of U.S. patent application publication no. 2023/0000001
Excerpt of the first page of text of US 2023/0000001 A1 for an "Assembled Garden Tool" showing two-column format with paragraph numbers
Example excerpt from first page of text of U.S. patent application publication no. 2023/0000001

The published application might also include amendments, such as amendments to the claims or drawings. In some uncommon instances, amendments might be published that are later disallowed and omitted from a subsequent granted patent. But amendments submitted too late for inclusion might not be included with the publication. And appendices included in patent applications are generally not published. The USPTO can refuse to publish certain information prohibited by law or that is offensive or disparaging. Additionally, as a consequence of official preparations and formatting efforts for publication, there can sometimes be discrepancies and printing errors, in which the published version unintentionally differs from the applicant’s original application.

In some other jurisdictions, such a PCT application publications, published applications merely take copies of the application as filed by the applicant and add a cover sheet. In other words, the application is not reformatted and reflects what the applicant submitted.

Publication Numbers

Each patent application publication is assigned an official publication number. In the USA, and with PCT matters, the publication number differs from the application serial number assigned upon filing by the relevant patent office. Although in some jurisdictions the publication number may be the same or nearly the same as an application serial number.

The anatomy of a publication number in the USA is shown as follows:

graphic labeling the country code, pub. year, unique number and kind code for the publication number of U.S. patent application publication no. US 2023/0000001 A1
Anatomy of a U.S. patent application publication number

There is a four-digit year followed by a slash followed by a seven-digit number unique to each published application, and the concluded with a kind code. The unique-seven digit numbers are sequentially assigned to each newly published application. The kind code indicates the type of publication, with “A” generally indicating a published application and “B” generally indicating a granted patent. A two-letter country-code prefix to patent publication numbers can also be present, or appended, to indicate the jurisdiction of the patent publication.

Be aware that some patent searching databases use confusing variations on official patent publication numbers and kind codes. For instance, the Espacenet portal from the European patent Office (EPO) truncates U.S. published application numbers and shortens the unique seven-digit number to a six-digit number (but dropping a leading zero). Also, some databases will retroactively apply an “A” kind code to old granted U.S. patents, from before the USPTO began printing kind codes on patents or making pre-grant publications at all.

Each jurisdiction has a slightly different format for publication numbers. For instance, PCT publication numbers have a “WO” country-code prefix and use a six-digit unique identification number.

Example publication number for PCT international publication number WO 2023/000001 A1, published in German
Example publication number for PCT international publication number WO 2023/000001 A1

Publication Makes File Wrapper Available Too

Before publication, the substantive contents of pending patent applications are kept confidential by the U.S. Patent & Trademark Office (USPTO). But upon publication, which normally happens after eighteen months from the earliest priority date, the file wrapper of a published patent application is also made public by the USPTO. This allows the public to monitor the status and ongoing prosecution history of the corresponding application. While the “published application” is a discrete, stand-alone document, its publication also makes other information publicly available too. But, strictly speaking, a published application refers only to the stand-alone published version of the application and not to other materials in a file wrapper made available to the public through other channels.

Differences From a Granted Patent

A published patent application is much different from a granted patent (also called an issued patent). This is often misunderstood. Although the differences between published applications and granted patents are very significant.

In all but a few countries, patent applications must undergo a substantive pre-grant examination that establishes patentability before a patent is granted. A pre-grant patent publication merely indicates that the applicant(s) are seeking—or previously sought—a patent. But there are no enforceable patent rights unless and until a patent is granted. The existence of a published application for an application that is still pending simply means that a patent might be granted. Plus, the scope of the claims in any later-granted patent may differ from those in the published application. By way of analogy, just because someone files a lawsuit does not mean that he or she will win the case or that all the allegations are all true.

A common mistake is to refer to a published patent application as a patent. But they are not patents! It is reasonable to call them patent documents, or patent-related documents. But a published application is not directly enforceable by itself. Only a granted patent can be enforced. This is the most important distinction. A published patent application does not present immediate and direct infringement risks like a granted patent. Although the technical teachings and disclosures in a published patent application may still be prior art against later patent application claims. Yet a published application and a later related patent are often merely cumulative, meaning (apart from different publication dates) they are redundant in terms of their substantive teachings.

Another potentially confusing aspect of published patent applications is that you cannot understand the current status of the underlying patent application from the published patent application alone. A given published application may have matured into a granted patent since publication, or might have been abandoned (and/or another related “child” application might have been filed too). It is necessary to look up the current status in official records, such as though the USPTO’s Patent Center portal. Most paywalled, proprietary patent searching databases provide at least some status information, and a few (but definitely not all) free, open-access patent searching databases provide some status information. But finding and interpreting current status information is not always straightforward.

Photo of Austen Zuege

Austen Zuege is an attorney at law and registered U.S. patent attorney in Minneapolis whose practice encompasses patents, trademarks, copyrights, domain name cybersquatting, IP agreements and licensing, freedom-to-operate studies, client counseling, and IP litigation. If you have patent, trademark, or other IP issues, he can help.

Categories
Patents Q&A

When Are Patent Applications Published?

Most patent applications are normally published while still pending and prior to the grant/issuance of a patent. Such publication allows the public to see the contents of the application and expands the publication of technical information to include applications that do not turn into granted patents. But when does this pre-grant publication normally occur? And are there any exceptions or variations in the normal publication schedule? This article addresses issues around when patent applications are published occur prior to grant.

When Publication Normally Occurs

In the USA, any new utility or plant patent application is normally published after eighteen (18) months have elapsed from the earliest filing date. The 18-month publication period is based on the earliest effective filing date or priority date. So if there was a prior provisional or foreign priority application, or the application is a continuing application, the 18-month timeline runs from the earliest priority or “parent” application’s filing date rather than the filing date of the current application. Publication normally occurs as soon as possible after the 18-month deadline arrives. In practice, there may be administrative delays in publication. As a result, it might not always happen at exactly eighteen months.

However, U.S. design patent applications and provisional patent applications are never published before grant (35 U.S.C. § 122(b)(2)(A)). Also, reissue patent applications are not published because they always relate to a prior patent that was already granted and therefore already publicly available.

PCT international patent applications are also published after eighteen months (PCT Art. 21). Most other jurisdictions publish patent applications after eighteen months too. Sometimes this public availability in other countries is referred to as providing “laid open” patent applications.

Exceptions to the Normal Publication Schedule

There are some exceptions to the default 18-month pre-grant publication of utility and plant patent applications.

Sometimes pre-grant publication is delayed or does not occur at all. In the USA, applicants can expressly request non-publication, which is only possible if no foreign patent protection is sought. If a non-publication request is filed, the patent and related file wrapper contents only become accessible when a patent is granted, if at all. There can also be secrecy orders that delay publication (and grant of a patent) when the application’s subject matter implicates national security interests. And applications that are no longer pending at eighteen months are not published. That situation arises if a patent is granted in less than eighteen months or if an applicant files a timely express abandonment request.

It is also worth noting that pre-grant publication only began in the U.S. starting with applications filed on or after November 29, 2000. So pre-grant publications simply did not exist in the USA prior to that time frame. Although pre-grant publications have existed in many other countries for a much longer time.

Occasionally pre-grant publications will occur earlier than the usual 18-month schedule. For instance, applicants in the U.S. can expressly request early publication and/or republication, although such requests are rare.

Photo of Austen Zuege

Austen Zuege is an attorney at law and registered U.S. patent attorney in Minneapolis whose practice encompasses patents, trademarks, copyrights, domain name cybersquatting, IP agreements and licensing, freedom-to-operate studies, client counseling, and IP litigation. If you have patent, trademark, or other IP issues, he can help.

Categories
Patents Q&A

What Is Prior Art?

The phrase “prior art” is used extensively in relation to patents and patenting. But what is prior art? What does this term refer to? The following article will explain how this term is used in patent law.

Basic Overview

Prior art refers to what was already known that is relevant to patentability. More particularly, it is qualifying existing knowledge that is relevant to questions of novelty and nonobviousness (or inventive step), which are two requirements for patentability, for an invention recited in a given claim of a patent or patent application.

Of course, there are some further nuances here about what exactly is considered relevant to patentability and what is not, and what legally qualifies as prior art under applicable law. Many of those nuances are explained further below.

Prior Art is Old Knowledge

First of all, prior art has to be old enough. It always has to be something that was already known or came before before a particular date associated with a given patent or patent application. So the “prior” part of the term “prior art” means something was known sufficiently earlier or before what given inventor(s) are claiming is their patentable invention. This is about dividing technical knowledge into older stuff that might call the patentability of an invention into question and later stuff that might infringe claim(s) of a patent to that invention.

For any given patent or patent application, there is a critical date that establishes what is old enough to be prior art. Something before the critical date is prior art and anything after is not. The point in time that constitutes a critical date will be established by the patent laws of a particular jurisdiction. It can vary based on whether a jurisdiction follows a first-to-file patent system or a first-to-invent patent system, for example. It can also vary on a claim-by-claim basis—there may be different priority dates for different claims, which means some things may be prior art against certain claims but not others.

Prior Art is Knowledge of Useful Arts

The “art” part of the term “prior art” refers to knowledge about the useful arts. The “useful arts” is basically an old-fashioned term that refers to technical knowledge pertaining to what today is more commonly called science and engineering. Just as there are different fields of science and engineering, there are different types of arts. So this term is not limited to any particular area or kind of technical knowledge. But it does not refer to paintings, sculptures, or similar artworks that might appear in a museum.

The term “prior art” can refer to the collective body of relevant prior technical knowledge. That means it is proper to say that something falls within the prior art, as in being a part of that body of pre-existing knowledge. It is common to refer to a “prior art reference”, “prior art product”, or the like in reference to a particular instance of something that qualifies (or allegedly qualifies) as prior art.

Prior Art is Essentially Public Knowledge

In general, prior art refers to information that was sufficiently accessible to the public. This might have been in the form of commercially-available products or services, or in the form of articles, books, videos, etc. Importantly, something that was “secret” and not available to the public usually will not qualify as prior art. For instance, an unpublished draft of a book or article will not qualify as prior art. But there are some exceptions that may allow certain secret or confidential activities to qualify as prior art, mainly relating to confidential on-sale activities.

A crucial exception (at least in the USA) is that any sale or offer for sale can potentially qualify as prior art. The U.S. on-sale bar still applies to prior confidential, private, or otherwise secret commercial sales or offers for sale. In other words, a confidentially or non-disclosure (NDA) agreement will not remove something that was on sale from the realm of prior art. Such confidential sales still involve a third-party (who is part of the public) gaining access to an invention. Also, inventor(s)’ own prior activities can potentially be used as prior art against the inventor(s)’ later patent application or patent, unless the inventor(s)’ application was filed in the statutory grace period.

Laws Vary By Jurisdiction

Prior art is also something defined by the patent laws of a given jurisdiction. This means that definitions of what is and is not considered prior art can and do vary between different countries. There is no universal harmonization of patent laws in this respect. So it is possible something might qualify as prior art in one country but not in another.

In the USA, what constitutes prior art is set out in § 102 of the patent laws (35 U.S.C. § 102). This portion of the current patents laws is written in a very confusing manner. But it establishes that prior art can include a patent, a published patent application, a printed publication (which can also include patents and published patent applications), products or processes that were in public use or on sale, as well as things that were otherwise available to the public before the effective filing date of the claimed invention. U.S. patent law also contain some exceptions that can disqualify certain references from being used as prior art.

In other countries, however, the patent laws may differ significantly. For instance, some countries have no on-sale bar, only a public use bar to patenting. This means that secret or confidential sales may not qualify as prior art, even if those prior secret sales involved the identical invention. And few other countries have a filing grace period like the U.S. Some jurisdictions may also have limits on the use of prior art, such as making an applicant’s prior patent applications available as prior art only for novelty determinations but not inventive step/obviousness determinations. It is important to consider laws of each relevant jurisdiction separately, because differences in laws can mean that what qualifies as prior art differs between jurisdictions.

Laws Change Over Time

What qualifies as prior art can also change over time in a given jurisdiction as laws are modified or interpreted by courts.

U.S. patent laws have changed over time, including modifications to the definitions of what does and does not qualify as prior art. Significantly, the America Invents Act (AIA) had provisions that went into effect March 16, 2013 that eliminated certain first-to-invent provisions and altered other aspects of what qualifies as prior art. For example, the AIA eliminated certain geographic restrictions on what qualifies as prior art—no longer requiring that certain things happen in this country (i.e., in the USA) to be prior art. Patents and patent applications with pre-AIA effective filing dates are therefore subject to different definitions of what qualifies as prior art than post-AIA ones. Laws in other countries have also changed over time.

Photo of Austen Zuege

Austen Zuege is an attorney at law and registered U.S. patent attorney in Minneapolis whose practice encompasses patents, trademarks, copyrights, domain name cybersquatting, IP agreements and licensing, freedom-to-operate studies, client counseling, and IP litigation. If you have patent, trademark, or other IP issues, he can help.

Categories
Articles

New and Upcoming Changes in U.S. Patent, Trademark, & Copyright Law for 2024

Important Developments

As 2024 begins, some recent and upcoming changes in practice at the U.S. Patent & Trademark Office (USPTO) for patent and trademark matters and at the U.S. Copyright Office for copyright matters merit attention, along with developments from U.S. courts pertaining to those areas of intellectual property (IP) law. (Click the preceding links to jump to desired content).


Patents

Non-DOCX filing format requirements postponed (yet again)

The deeply unpopular surcharge for U.S. non-provisional utility patent applications in a non-DOCX file format has been postponed yet again, until January 17, 2024.  Although even when in effect this surcharge will not apply to PCT national phase entries, provisional applications, plant applications, or design applications.  Furthermore, the USPTO has indefinitely extended a highly limited opportunity to file a back-up applicant-generated “Auxiliary PDF” version of an application filed in DOCX format, in order to potentially allow for later correction of USPTO-side conversion errors involving the DOCX version. These postponements and extensions are the result of many strong objections from U.S. patent practitioners and practitioner organizations. 

It remains to be seen whether there will be further postponements or a larger change in USPTO policy about mandatory DOCX filings, which in general provides only a small clerical benefit to the USPTO while placing large burdens and costs on applicants. 

Guidance for creating application documents (hopefully) compliant for USPTO DOCX filing is available here.  But applicants with complex application content should consider the possibility of paying the non-DOCX official surcharge and filing applications in PDF format to avoid the risks associated with USPTO-generated errors in substantive application content. 

Electronic patent “eGrants” now in place

On April 18, 2023, the USPTO began issuing an electronic PDF copies of patent “eGrants” as the official versions of granted patents.  Continuing a long tradition, patent eGrants are issued on Tuesdays. As of December 2023, “ceremonial” paper copies were still being automatically sent as part of a transition period.  The end date of that transition period, when paper copies will no longer be sent, has not been specified.  Whenever the transition period does end, paper copies of patents can still be ordered from the USPTO for a small official fee (currently $25). However, ordered copies will either be a certified copy of the entire patent (which lacks the decorative color cover like eGrants and instead includes a certification cover page) or a “presentation” patent (which is a partial certified copy of only the front page of the patent, with a unique certification statement and special seal). Both of those differ from current “ceremonial” copies.

Of note, any color drawings in patents do appear in color in the new electronic patent eGrants. This potentially reduces the need to specially order color copies.

Further, the USPTO will also begin issuing certificates of correction electronically starting January 30, 2024. Paper hard copies of certificates of correction will not be mailed after that date, although they can still be specifically requested for a fee like other patent documents.

Massive official fee increases proposed, but implementation unclear

In April of 2023, the USPTO announced plans for significant official fee increases.  Materials related to those efforts can be found here, including an Executive Summary of the key official patent fee increases proposed.  If implemented, many fees would be increased by 25% and some by over 700%!  And some wholly new fees are proposed. The Executive Summary should be consulted for more details because of the sweeping extent of the proposed fee schedule changes. 

For example, the USPTO has proposed tiered fees for continuing applications (with large fees required if a continuing application is filed more than three or seven years after earliest parent’s filing date), new fees if the number of citations submitted with information disclosure statements (IDSs) exceed tiered thresholds, higher excess claim fees, more steeply increasing subsequent request for continued examination (RCE) fees, new fees for After-Final Consideration Pilot (AFCP) 2.0 requests, reinstating and increasing fees for assignment recordations submitted electronically, and enormous increases in design application fees.  The design application fee increases are being driven by the prevalence of mostly foreign applicants filing expedited examination requests as micro entities, which has created a large backlog of non-expedited design applications. 

While the USPTO currently has fee-setting authority “only to recover the aggregate estimated costs to the Office,” many of the proposals would appear to exceed that authority to try to shift or discourage certain actions by applicants.

At present, the USPTO has not made further announcements in response to comments about its patent fee proposals.  Some changes to the initial proposals are certainly possible.  But extremely large official patent fee increases are likely by January 2025. More official information should be available sometime in the first quarter of 2024.

Design patent 1 million issued and design patent bar created

In 2023 the USPTO issued design patent 1,000,000.  Also, the USPTO authorized a design patent-specific bar for practitioners without scientific or engineering backgrounds to prosecute design cases.  This new design patent bar does not restrict the ability of other patent practitioners to handle design applications.  Regular patent practitioners with scientific or engineering backgrounds are still able to handle any and all types of patent applications, for utility, design, or plant matters.  But practitioners admitted to the new design patent bar will not be able to handle utility or plant patent applications. Other developments in the courts related to design patent practice are discussed below.

Suggested figure for publication policy changed

Applicants were previously able to suggest a figure to appear on the front page of a pre-grant publication of a patent application, but the USPTO independently decided which figure to publish on the front page and sometimes chose a different one.  That policy has changed.  The USPTO now exclusively uses the drawing figure suggested by the applicant for the front page of the pre-grant publication when that suggestion is included on a compliant application data sheet (ADS) that is timely filed before the USPTO begins its process of publishing the application.  Despite this change, it is still common (and often recommended) for applicants to allow the USPTO to select a figure for publication on the front page and not suggest one. 

Changes to USPTO online systems

On November 15, 2023, the USPTO permanently retired its PAIR and EFS-Web systems.  This leaves only the USPTO’s Patent Center for making electronic filings and retrieving file histories.  Although the USPTO has said that Patent Center provides all the functionality of the retired systems, that is not accurate.  For instance, without any formal announcement, the USPTO deactivated its First Office Action Estimator tool.  In truth, that estimator tool had ceased to be accurate for some time.  But applicants are now left with no mechanism to estimate the time until substantive examination begins.  Patent Center has reduced functionality in numerous areas and practitioners have found it to be prone to bugs and usability problems, including a lack of capacity. 

The USPTO has also announced a plan to “reform” the Electronic Trademark Assignment System (ETAS) and the Electronic Patent Assignment System (EPAS) into one cohesive and modernized system called the Intellectual Property Assignment System (IPAS). IPAS is slated to be available starting January 15, 2024 [UPDATE: the transition date was pushed back to February 5, 2024].  No further details are available at this time, so it is unclear how the new assignment system will differ or what the apparently integrated patent and trademark recordation interface will look like. 

More U.S. patent filing information

Please also see the Guide to Foreign Priority Patent Filings in the USA for in-depth discussion of requirements for foreign applicants to file U.S. counterpart patent applications with a foreign priority claim. Additional basic information about patenting can be found in the Patent Basics guide.


Trademarks

Fee increases proposed

In May of 2023, the USPTO announced plans for official trademark fee increases.  Materials related to those efforts can be found here, including an Executive Summary of the key official trademark fee increases proposed.  If implemented, the naming convention and types of fees would change.  For example, a typical trademark application would see at least a $100 fee increase.  And, if custom identifications of goods/services are used rather than merely selecting ones from pre-approved descriptions from the Trademark ID Manual, then new “premium” surcharges of $200 per class would apply.  This means that many (if not most) new trademark applications will see official filing fees increase by at least $300, and possibly more if there are multiple classes of goods/services.  Somewhat similar fee structure changes and official fee increases would apply to Madrid Protocol extensions to the USA too.  Various other fees will increase 10-66% or more, including a 400% increase in the fee for a letter of protest, for example. 

At present, the USPTO has not made further announcements in response to comments about its trademark fee proposals.  Some changes to the proposals might be made, but significant official increases are a certainty. More information should be available from the USPTO in the first quarter of 2024, and the new fees are expected to go into effect by November 2024.

New trademark search and assignment recordation tools

The USPTO retired its Trademark Electronic Search System (TESS) on November 20, 2023.  A new Trademark Search tool has been made available in its place.  The new tool has a more modern-looking interface. It still includes search functionality similar to that of TESS, but no longer times out during searches. Also, it offers the ability to export search results and other information as a spreadsheet.  However, the USPTO has warned that the new Trademark Search system will sometimes display outdated status information, drawn from a Trademark Reporting And Monitoring (TRAM) system that the USPTO plans to retire sometime in 2024.  The most accurate trademark status information can be found instead in the USPTO’s Trademark Status and Document Retrieval (TSDR) system, which is linked in individual search results. Training materials on how to use the new Trademark Search tool are available.

As noted above regarding patent developments, a new trademark (and patent) assignment recordation system called the Intellectual Property Assignment System (IPAS) is slated to become available starting January 15, 2024 [UPDATE: the transition date was pushed back to February 5, 2024].

More U.S. trademark filing information

Please also see the Guide to Trademark Registration in the USA for in-depth discussion of requirements for foreign applicants to file U.S. federal trademark applications. Additional basic information about trademarks can be found in the Trademark Basics guide.


Copyrights

AI-generated works usually not copyrightable

The U.S. Copyright Office requires that works be authored by a human to be copyrightable.  In the generative AI context, authorship requirements begin by asking whether the work is basically one of human authorship, with the computer/AI merely being an assisting instrument, or whether the traditional elements of authorship in the work (literary, artistic, or musical expression or elements of selection, arrangement, etc.) were actually conceived and executed not by a human but by a machine.  The Copyright Office takes the view that when an AI tool solely receives a prompt from a human and produces complex written, visual, or musical works in response, such prompts function like instructions to a commissioned artist and the person making the prompts is not considered an author.  Accordingly, in that situation the resultant AI-generated work is not protectable by copyright.  On the other hand, if AI-generated elements are further selected and arranged by a human, those aspects may be protectable, with the non-copyrightable AI-generated elements disclaimed. 

In copyright registration applications, applicants have a duty to disclose the inclusion of AI-generated content and to provide a brief explanation of the human author’s contributions to the work.  Given the interest in this area, the Copyright Office has an ongoing initiative and inquiry.  Applicable policies and legal standards may continue to evolve. 


Significant Developments in U.S. Courts

Patent enablement requirements reinforced

The U.S. Supreme Court unanimously ruled in Amgen v. Sanofi that “[i]f a patent claims an entire class of processes, machines, manufactures, or compositions of matter, the patent’s specification must enable a person skilled in the art to make and use the entire class.  In other words, the specification must enable the full scope of the invention as defined by its claims. The more one claims, the more one must enable.”   This important decision reaffirmed a principle set out in cases going back more than a century, which preclude the grant of a patent monopoly extending beyond the invention actually disclosed.  In this way, a central underlying premise of modern patent law was confirmed, that of a quid pro quo or “bargain” between the inventor(s) disclosing the invention and the public granting a limited monopoly in exchange.  The Court discussed famous historic cases, including those involving Samuel Morse and Thomas Edison, as setting out the same enablement requirements. 

In the Amgen case, in particular, the central issue revolved around the use of functional claim language that encompassed an entire genus of embodiments of antibodies coupled with the disclosure of inadequate teachings and embodiments pertaining to only a subset of species within that genus.  The patentee Amgen had disclosed only a few (26) working examples plus a roadmap for a trial-and-error process that would have involved undue, “painstaking” experimentation to arrive at the entire claimed genus (encompassing at least millions of candidates).  This was found inadequate and so the invalidation of the relevant claims for lack of enablement (under 35 U.S.C. § 112(a)) was affirmed. 

A specification may call for a reasonable amount of experimentation to make and use a patented invention.  Often that can be done by disclosing a general quality or general rule that may reliably enable a person skilled in the art to make and use all of what is claimed (and not merely a subset).  But what is reasonable in any case will depend on the nature of the invention and the underlying art.  Although not explicitly discussed in the Amgen case, courts have long recognized a distinction between so-called “predictable” arts like those involving mechanical and/or electrical inventions and “unpredictable” arts like those involving chemical and biotech inventions, as well as the amount of knowledge in the state of the art available to a person of ordinary skill.  The more predictable the art, and the more knowledge a person of ordinary skill in the art would have, the less disclosure is required for enablement.  Although even in the “predictable” arts enablement issues can arise, especially where “preemptive” functional or result-only claim language is used.

[Edit: in January 2024, the USPTO released guidance regarding the enablement requirement for utility patent applications in view of Amgen v. Sanofi. Existing USPTO practice of following the so-called Wands factors were essentially reaffirmed.]

Treatment of design patents continues to change

U.S. design patent practice has seen a number of significant shifts and important court decisions in recent years.  Notably, there is currently a case called LKQ Corp v. GM Global Tech. Operations LLC pending rehearing that will clarify obviousness standards for designs, and how that standard is the same or different from obviousness for utility patents.  At stake is whether design patents will be treated uniquely, with essentially a lower threshold for patentability (currently, obviousness is more difficult to establish for designs), or subject to basically the same non-obviousness standard as for utility patents. 

Another controversial decision in the Columbia II case limited the use of “comparison” prior art in infringement analysis to highlight similarities or differences between the patented design and the accused product that might not otherwise be apparent to an ordinary observer.  That case built upon recent emphasis on the title of design patents being limiting, and expanded on a prior case (In re Surgisil) that said only prior art pertaining to the same type of article claimed can be used for patentability analysis, even though prior precedential cases had said that considerations about use of an article are immaterial.  The main takeaway is that the law around design patents continues to shift, and at least some judges have attempted to expand or strengthen design patentees’ power in ways that seem to depart from binding precedent. 

District of Delaware holds patent case plaintiffs accountable

Chief District Judge Colm Connolly of the District of Delaware has implemented a standing order requiring disclosure of third-party litigation funding. This policy differs from some other districts (and other judges) that refuse to require such disclosures, even in response to discovery requests. These disclosure requirements help to identify real parties in interest to allow for recusal of the judge if a conflict of interest arises due to the judge having an ownership interest in the litigation funder.

In a set of patent cases brought by non-practicing entities believed to be connected to a common litigation funder, Chief Judge Connolly has issued sanctions and referred attorneys and a party to criminal prosecutors and state bars responsible for attorney licensing. These stem from allegations that the litigation funder is directing the litigation and attorneys are taking instructions from entities other than the named party in the lawsuit, which may constituent the unauthorized practice of law and/or a breach of attorney ethical obligations.

In at least one other case, these policies have also led to dismissal where litigation funder confidentiality agreements have precluded compliance with the Chief Judge’s funding disclosure requirements.

The significance of these probes and disclosure requirements is that these patent lawsuits are generally brought by corporate entities formed only for the purpose of bringing a patent lawsuit, and which have essentially no assets. The lack of assets by a shell company is used by litigation funders to try to shield themselves from liability for possible sanctions and attorney fee awards for bringing meritless or objectively baseless lawsuits. Occasionally, similar cases have involved accusations of sham assignments, which can impact the standing of the plaintiff to bring suit if ownership rights are illusory. These policies also bolster and supplement corporate disclosure requirements under Federal Rule of Civil Procedure 7.1, which on its face does not address things like contractual obligations that can curb settlement power or incentives, or when an entity has the power to control another through “negative control” or economic dependence standards applied by the U.S. Small business Administration to determine “affiliate” status and in turn to determine USPTO entity size status.

More generally, Chief Judge Connoly’s policies present some long-overdue limits on the use of courts to extract nuisance settlements, a problem that has been well-documented with respect to so-called “patent trolls”.

Prosecution laches

Certain cases have continued to apply so-called “prosecution laches” to render patents unenforceable. Prosecution laches is premised on prejudice to an accused infringer by the patentee’s unreasonable and inexcusable delay in prosecution of the asserted patent. Cases that apply this doctrine typically involve continuing applications. Recently, this doctrine has been applied in prominent cases by independent inventor patentees. These cases merit attention for a number of reasons. The criticized “egregious misuse” of the patent system is not something confined to a few isolated instances, but is rather commonplace. For instance, similar conduct in creating patent thickets with multiple continuation applications is routine in medical device patenting. And it is not uncommon for patentees to write claims in continuing applications to cover competitor products. Most significantly, the application of a laches defense is in tension with the Supreme Court’s 2017 SCA Hygiene decision saying that laches cannot be invoked as a defense against a claim for damages brought within the six-year limitations period of 35 U.S.C. § 286. The crucial issue is whether (or when) a judge-made policy can preclude use of statutory provisions allowing continuing applications. Also notable is reliance on unenforceability rather than, for instance, invalidity based on lack of enablement—many continuing applications of the sort that raise these questions would seem to be vulnerable to allegations of lack of enablement in the original disclosure, which is a statutory requirement.

Double patenting and patent term adjustment

In the In re Cellect case, the Federal Circuit held that patent term adjustment that differeed among patents in a family led to invalidity for obviousness-type double patenting, because the patents did not expire on the same date. This case is notable because it held that the judicially-created doctrine of double patenting led to unpatentability as a result of USPTO delay, despite the fact that this stemmed from a statutory provision (35 U.S.C. § 154) granting patent term adjustment. In other words, it presents a significant judicial/legislative separation of powers issue. On the other hand, double patenting concerns only arise when a patentee chooses to file multiple patent applications with overlapping scope.

Normally, double patenting can be overcome by filing a terminal disclaimer. But the In re Cellect case presented an unusual situation. It involved a reexamination of an already-expired patent, and terminal disclaimers are not permitted for expired patents. However, the decision in that case still established that a patent can be invalidated or found unpatentable as a result of USPTO delay, thus requiring terminal disclaimers in more situations than was generally believed necessary previously.

Copyright mandatory deposits found unconstitutional

The Court of Appeals for the D.C. Circuit has ruled in the Valancourt Books v. Garland case that the mandatory deposit requirement of the copyright laws (17 U.S.C. § 407) is unconstitutional under the Takings Clause of the Fifth Amendment of the Constitution. Mandatory deposits provided copies of works for archiving by the Library of Congress. Although some form of mandatory deposit requirement has been in place since the first copyright law was passed in 1790. But the D.C. Circuit ruled that subsequent amendments to the copyright laws had left mandatory deposits “untethered” from the benefits of copyright registration, rendering them a government taking without compensation prohibited by the Constitution. Penalties for failing to make a mandatory deposit will no longer apply.

Fair use eviscerated by Supreme Court

In a pair of rather shocking decisions (Jack Daniel’s and Andy Warhol Foundation), the U.S. Supreme Court has greatly limited “fair use” defenses with respect to both trademarks and copyrights.  These decisions greatly reduce freedom to operate based on parody or artistic transformation defenses that were largely taken for granted for a long time under U.S. law, and reflect unconvincing treatment, if not outright disregard, for both fact and law.  A return to prior treatment of fair use will apparently require legislative action, which is not likely in the near future. 

Role of fraud in trademark matters

In the Great Concepts v. Chutter decision, the Federal Circuit held that fraud in a declaration of incontestability (under § 15 of the Lanham Act, 15 U.S.C. § 1065) cannot be used as a ground to cancel a trademark registration. This creates a split with the Ninth Circuit’s prior 1990 decision in Robi v. Five Platters, which held that a statement of incontestability that fraudulently asserted that there were no adverse decisions involving the registered mark justified cancellation. This means that this particular ground for challenging a registration will only be available in courts and not in Trademark Trial and Appeal Board (TTAB) administrative cancellation proceedings.

Significantly, the Federal Circuit did not reach a major point from the appealed TTAB Great Concepts decision holding that recklessness was sufficient to establish fraud.  The Federal Circuit has generally taken an idiosyncratic view of fraud, and numerous past decisions (not limited to trademark law) have made it difficult to prove fraud—despite (or rather because of) the prevalence of accusations and circumstantial evidence of fraud.  This issue is also loosely tied to the contentious Iqbal/Twombly “plausibility” pleading standards, which altered longstanding notice pleading requirements, and which research has shown allows judges to limit access to the courts (and associated evidentiary discovery) for certain types of claims for ideological reasons. 

Crisis of legitimacy in judiciary continues

U.S. Supreme Court justices have been mired in ethics scandals and public confidence in the Court remains at or near record lows.  These scandals have revolved around essentially influence/bribery concerns and deficient disclosure of income and “gifts” that call into question judicial impartiality.  There was a recent introduction of a code of conduct formulated by the Supreme Court justices themselves with no clear enforcement mechanism—with the justices apparently taking the position that they have already been compliant with the new code of conduct, as an attempt to deflect the serious charges leveled against them rather than meaningfully address them.  The judiciary’s self-policing has been criticized in general. 

Specifically in the IP field, on September 20, 2023 Judge Pauline Newman was suspended for one year from the Federal Circuit, the court with exclusive appellate jurisdiction over patent lawsuits.  At 96 years old, she is the oldest current serving U.S. federal judge, appointed by President Regan in 1984.  Her suspension resulted from her refusal to cooperate with an investigation into her fitness due to health issues and her treatment of court staff.  As of December 2023, she has still refused to either retire or cooperate with the official investigation, a course of conduct that has reflected poorly on her and, more broadly, has tarnished the reputation of the judiciary as a whole.  Judge Newman continues to challenge her suspension and the investigation as a whole—on “libertarian” grounds that deny government authority and therefore sit uncomfortably with her role as a federal judge. 

Additionally, an employment-related complaint by an administrative patent judge (APJ) at the USPTO for abuse of authority was initially sustained in May of 2023. The APJ had reported interference with Patent Trial & Appeal Board (PTAB) judge assignments through “panel stacking” in order to alter case outcomes (in a separate Freedom of Information Act [FOIA] case, the USPTO refused to disclose how often this occurred). Supervisors then retaliated against him. This matter points to more general transparency and credibility problems and a lack of independence of administrative judges (within the executive branch). It follows a 2022 Government Accountability Office report finding that a majority (67%) of APJs felt pressured by management to alter specific decisions in AIA proceedings and a smaller but still significant number (34%) felt similar pressure in ex parte appeals. It further follows the Supreme Court’s 2021 Arthrex decision, which held that APJ appointments violated the Appointments Clause of the Constitution but that such deficiencies were resolved by allowing PTAB decisions to be reviewed by the Director of the USPTO—essentially undermining APJ independence and objectivity in favor of protecting the political aspects of appointment authority. These issues also recall concerns about secret USPTO actions during application examination placing public relations / perception management concerns ahead of objective patentability requirements established by the legislature.

To foreign observers, the crisis of legitimacy in the U.S. judiciary might seem to merely extend a legitimacy problem with U.S. government action both domestic and worldwide, including investigations/proceedings against presidents past and present and conduct before bodies like the United Nations. 

December 2023
Photo of Austen Zuege

Austen Zuege is an attorney at law and registered U.S. patent attorney in Minneapolis whose practice encompasses patents, trademarks, copyrights, domain name cybersquatting, IP agreements and licensing, freedom-to-operate studies, client counseling, and IP litigation. If you have patent, trademark, or other IP issues, he can help.

Categories
Articles Patents

Patent Marking Program

Materials from a presentation by Austen Zuege about patent marking in the United States are available here:

“Patent Marking: Legal Standards and Practical Issues”

These downloadable materials from a past live presentation address basic marking requirements and best practices for patent marking, as well as requirements for virtual marking, alternative marking on a label or package, ways the sufficiency of marking can be challenged, and false marking. These materials cover the ins and outs of patent marking in a format packed with real-world examples.

Marking is simple enough in concept but there are a surprising number of nuances and practical challenges for implementation. Also, the America Invents Act (AIA) reshaped numerous aspects of marking that continue to reverberate. For instance, virtual marking was introduced with the AIA and there is now a growing body of court decisions clarifying what kinds of virtual marking practices are sufficient and what kinds are not. These practical aspects of marking are addressed in these program materials.

More information about patent marking is available in this detailed guide and this brief overview.

Photo of Austen Zuege

Austen Zuege is an attorney at law and registered U.S. patent attorney in Minneapolis whose practice encompasses patents, trademarks, copyrights, domain name cybersquatting, IP agreements and licensing, freedom-to-operate studies, client counseling, and IP litigation. If you have patent, trademark, or other IP issues, he can help.

Categories
Patents Q&A

How Can I Calculate Patent Term?

Patents have a maximum term and cannot be renewed. This is part of the quid pro quo underlying modern patent law. The patentee gets exclusive rights for a limited time but then the technology disclosed in expired patents can be freely used by the public (in at least the jurisdiction that issued the patent). Knowing how to calculate patent term is therefore important in order to determine when a given patent has expired. But, for better or worse, the term of any given patent can vary. There is no single fixed term for all U.S. patents. And the applicable term is not always apparent on the face of a given patent. So how is patent term calculated for U.S. patents?

USPTO Patent Term Calculator

One of the simplest and most practical ways to determine the term of a given U.S. patent is to utilize a patent term calculator provided by the U.S. Patent & Trademark Office (USPTO). Using this downloadable spreadsheet requires inputting certain information about a given patent. Only some of the necessary information appears printed on a granted patent. Other information must be researched in USPTO records, mainly through Patent Center.

The advantage of the USPTO’s patent term calculator is that it can be used by anyone, even people who do not understand the applicable patent laws. However, it still requires ascertaining the correct information to enter in the spreadsheet. That requires knowing where to find such information. The patent term calculator also requires a level of confidence that the correct information is being entered. That is, it still requires knowing some of the terminology so that correct, relevant information is entered.

Read on for more information about the sorts of information relevant to proper patent term calculations.

Relevant Factors

What follows is a more detailed explanation of factors that determine the enforceable term of a given patent. These factors include factors that influence how to calculate a given patent’s term, as well as things that might cut short the enforceable term of a given patent. In any given instance, consulting with a knowledgeable patent attorney is recommend to determine the correct term of any given U.S. patent.

Type of Patent

Paten term first of all depends on the type of patent involved.

U.S. utility and plant patents have a basic term of 20 years from the relevant filing date (35 U.S.C. § 154)—there being some nuance about which filing date is used here.

timeline graphic of basic 20-year patent term
Timeline Showing Basic Patent Term for U.S. Utility and Plant Patents (Including PCT National Phase Entries)

A priority claim to a foreign patent application (stemming from the Paris Convention or a PCT application that did not designate the USA) or to a prior U.S. provisional patent application does not count against the term (35 U.S.C. § 154(a)(3)). This means a foreign priority or prior provisional filing can effectively extend patent term.

timeline graphic for basic patent term involving provisional or foreign priority
Timeline Showing Basic Patent Term for U.S. Utility and Plant Patents Based on a Prior U.S. Provisional or Foreign Priority Application

For regular PCT national phase entries to the USA, the PCT international filing date is used for term calculation (not the date of later U.S. national phase entry). That is, a PCT international application designating the United States is treated as a U.S. application (see 35 U.S.C. §§ 372 and 375), with the national phase being just a different phase of the same application. So an ordinary national phase entry into the United States does not, by itself, involve a “priority” claim–although there may additionally be a priority claim involved.

The so-called domestic benefit of a prior U.S. non-provisional application (that is, for a continuation, continuation-in-part, or divisional application under 35 U.S.C. §§ 120, 121, 365(c), or 386(c), including PCT “bypass” applications) does count against patent term, so the term calculation should be based on the earliest such prior filing date. In other words, continuing applications that have priority/domestic benefit of a prior U.S. non-provisional application will have a reduced patent term. The related U.S. application data field (INID code 63) on the face of a patent, if present, can indicate an earlier filing date that may impact term.

timeline graphic of basic patent term involving domestic benefit claim in continuing application
Timeline Showing Basic Patent Term for Continuing U.S. Utility and Plant Patents Based on a Prior Domestic U.S. Application (Including PCT “Bypass” Applications)
Excerpt of U.S. Pat. No. 11,102,682 showing: "Related U.S. Application Data (63) Continuation of application No. 15/090,600, filed on Apr. 4, 2016, now Pat. No. 10,667,181"
Example of INID code 63 “Related U.S. Application Data” field on front page of U.S. Pat. No. 11,102,682, showing earliest filing date for patent term calculation of a continuing application

In contrast, U.S. design patents currently have a fixed basic term of 15-years from the date of grant (35 U.S.C. § 173). The filing date issues referenced above do not impact design patent term. This means that continuing design patents can potentially have later expiration dates, unlike with utility and plant patents.

timeline graphic of design patent term
Timeline Showing Basic Patent Term for U.S. Design Patents

Reissue patents are possible “for the unexpired part of the term of the original patent.” (35 U.S.C. § 251). This means that a reissue patent’s term is no longer than the term of the original patent, as subject to any extension or adjustment. It is possible that a reissue patent’s term could be shorter than that of the original patent (see discussion of terminal disclaimers below). But reissue does not lengthen patent term.

Filing Date and Changes in the Law

The laws around patent term have changed over time. Some patents applied for or granted prior to those changes in the law may be subject to a different term.

U.S. utility and plant patents applications filed before June 8, 1995 can have a term of 17 years from the date or grant rather than from the earliest applicable filing date. Any patent that was in force on June 8, 1995 will have a term that is the greater of the 20-year term as discussed above or 17 years from grant (35 U.S.C. § 154(c)).

For U.S. design patents, those issued from design applications filed before May 13, 2015 have a 14-year term from the date of grant (rather than 15-years from grant).

Of course, there may be future changes in the law that affect patent term calculations. And courts may issue decisions that affect the interpretation of laws that impact patent term calculations.

Patent Term Adjustment

Certain delays in examination can lead to an adjustment of patent term for a given original patent (but not for a reissue). This is called patent term adjustment (PTA) under 35 U.S.C. § 154(b). Normally, this PTA is calculated as the number of days beyond the basic 20-year term that the patent can remain in force. The PTA period normally appears on the face of each granted patent—typically in a “Notice” field denoted with an asterisk (*). The USPTO’s Patent Center portal also has a menu tab showing detailed PTA calculations for a given patent. However, it is possible for a patentee to challenge the USPTO’s PTA calculation in some circumstances, meaning the PTA period might be corrected later. PTA does not apply to design patents.

Excerpt of U.S. Pat. No. 10,000,000 showing: "(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 430 days."
Example of PTA notice on front page of U.S. Pat. No. 10,000,000, showing 430 days of additional patent term

Patent Term Extension

Patentees can potentially obtain patent term extension (PTE) under 35 U.S.C. § 156 based upon premarket regulatory review of certain human drugs, food or color additives, medical devices, animal drugs, and veterinary biological products. This restores some term lost while awaiting premarket government approval from a regulatory agency. An application for PTE must be submitted within sixty (60) days of when permission for commercial marketing or use occurred. Patentees have to affirmatively apply for PTE, which is not automatically granted. Also, PTE is only possible for patents on certain types of subject matter; it does not apply to design or plant patents. § 156 PTE is not indicated on granted patents and must be researched in USPTO records, mainly through Patent Center.

Disclaimers

A given patent may be subject to a disclaimer (35 U.S.C. § 253). The two types of disclaimers are a terminal disclaimer or a statutory disclaimer.

In a terminal disclaimer, the patentee disclaims or dedicates to the public a portion of the term of a given patent. That is, the term of the patent is shortened from what it might otherwise be. Terminal disclaimers are frequently used to overcome double patenting, by disclaiming the period of patent term (if any) that would extend beyond that of one or more other patents. They are also used when design patent applications are revived after abandonment, disclaiming a period of patent term equal to the period of abandonment. Terminal disclaimers do not affect § 156 PTE, however.

Excerpt of U.S. Pat. No. 11,102,682 showing the notice: "This patent is subject to a terminal disclaimer"
Example of terminal disclaimer notice on front page of U.S. Pat. No. 11,102,682
Excerpt of terminal disclaimer filed against U.S. Pat. No. 11,102,682
Excerpt from example terminal disclaimer filed against U.S. Pat. No. 11,102,682, disclaiming term beyond that of U.S. Pat. No. 10,667,181

The USPTO has sometimes, but not always, printed an indication that a given patent is subject to a terminal disclaimer on the front page of the patent. Terminal disclaimers can also arise after a patent has been granted. In any event, the duration (and possibly also the existence) of a terminal disclaimer must be researched in the prosecution history of the relevant patent in USPTO records. This can generally be done using the online Patent Center portal and viewing the “Documents & Transactions”. Although the calculation of the disclaimed period may require additional research and analysis. For instance, it may be necessary to calculate the term of one or more other patents or the period of applicant delay for a design patent.

For statutory disclaimers, one or more claims of a patent are effectively surrendered. This means that some claims may no longer be in force, even though other claims might.

Lapse or Expiration for Non-Payment of Maintenance Fees

In order to keep a given U.S. utility patent in force, periodic maintenance fees are required (35 U.S.C. § 41(b)). These are due by four, eight, and twelve years from the grant of the patent. However, there are no maintenance fees required for U.S. design patents or plant patents (37 C.F.R. § 1.362(b)).

If a maintenance fee is not paid on time, then the patent will lapse or expire. This means that a given utility patent might no longer be in force even though it has not yet reached its maximum possible term.

What makes lapses/expirations complicated is that the patentee may be able to reinstate (that is, revive) the patent if a maintenance fee payment deadline was missed unintentionally. This may give rise to intervening rights (35 U.S.C. § 41(c)(2)). So, significantly, the expiration or lapse of the U.S. patent due to a missed maintenance fee may not mean the final and absolute end of rights in that patent if late payment is accepted.

Terminology describing this lapses/expiration for non-payment of maintenance fees has varied. The USPTO currently tends to use “expiration” but “lapse” is a better term because it differentiates situations where revival is possible from those in which a patent’s term has expired permanently because it has reached its maximum limit.

Invalidation and Cancellation

Patents can be invalidated by courts or cancelled by the USPTO, usually as the result of a challenge by another entity. This can affect all or merely some claims of a patent. Such an adverse ruling (after exhaustion of all rights of appeal) can end or limit rights in the patent short of its maximum possible term. It is necessary to research the existence and status of such an adverse ruling, if any.

Withdrawn Patents

Lastly, some patent numbers have been withdrawn by the USPTO. These were essentially never really patents in the first place, for various reasons, and thus have no term. Although, to complicate matters, the USPTO has also reinstated some previously withdrawn patents.

Laws Vary by Jurisdiction

The discussion above pertains only to U.S. patents. In other countries, laws may differ regarding the calculation of patent term, the availability of supplementary protection certificates, and so on.

Photo of Austen Zuege

Austen Zuege is an attorney at law and registered U.S. patent attorney in Minneapolis whose practice encompasses patents, trademarks, copyrights, domain name cybersquatting, IP agreements and licensing, freedom-to-operate studies, client counseling, and IP litigation. If you have patent, trademark, or other IP issues, he can help.

Categories
Articles

Federal Circuit Columbia Decision Both Clarifies and Muddies the Proper Use of Comparison Prior Art

When can prior art be used to assess alleged infringement of a design patent?  This has been an evolving area of U.S. patent law.  The question matters because looking at only the asserted patent and the accused product might not allow an ordinary observer to understand the ways in which the patented design is similar (or dissimilar) from known designs. A recent court decision sheds some light on the issue while at the same time muddies the waters in light of past cases that reached seemingly different results.

When assessing design patent infringement, “when the claimed and accused designs are not plainly dissimilar, resolution of the question whether the ordinary observer would consider the two designs to be substantially the same will benefit from a comparison of the claimed and accused designs with the prior art. . . .” Egyptian Goddess, Inc. v. Swisa, Inc., 543 F.3d 665, 678 (Fed. Cir. 2008) (en banc).  This is essentially a three-way visual comparison, in which differences “that might not be noticeable in the abstract can become significant to the hypothetical ordinary observer . . . .” Id. This is not about validity/invalidity but rather about how prior art informs the comparison of the patented design and the accused product to determine if there is infringement or not.

A recent Federal Circuit decision addressed what sort of prior art can qualify as comparison art.  In the second appeal in an ongoing dispute, a Federal Circuit panel held that “to qualify as comparison prior art, the prior-art design must be applied to the article of manufacture identified in the claim.”  Columbia Sportswear N. Am., Inc. v. Seirus Innovative Accessories, Inc., Nos. 2021-2299 and 2021-2338, Slip Op. at *21-23 (Fed Cir. Sept. 15, 2023) (“Columbia II“).

 In reaching that conclusion, the Columbia II panel cited one Supreme Court case from the 1800s, plus Egyptian Goddess and further said that “[s]imilar examples abound”.  But do they really?  The Columbia decision cites only a single post-Egyptian Goddess precedential case that was not abrogated (ABC Corp. I v. P’ship & Unincorporated Ass’ns Identified on Schedule “A”, 52 F.4th 934 (Fed. Cir. 2022)), plus one non-precedential case (Wallace v. Ideavillage Prods. Corp., 640 F. App’x 970, 971, 975–76 (Fed. Cir. 2016) (nonprecedential)). 

Two other case citations in Columbia II rely on portions of opinions (Arminak & Assocs., Inc. v. Saint-Gobain Calmar, Inc., 501 F.3d 1314, 1318, 1324–25 (Fed. Cir. 2007) and Unidynamics Corp. v. Automatic Prods. Int’l, Ltd., 157 F.3d 1311, 1313, 1324 (Fed. Cir. 1998)) that dealt with the “point of novelty” analysis that was specifically overruled by Egyptian Goddess, Inc. v. Swisa, Inc., 543 F.3d 665, 678-79 (Fed. Cir. 2008) (en banc).  Columbia II’s citations do not include any identifications any portions of the cited cases that were abrograted, or otherwise explain why or how specific aspects of those point of novelty analyses were still valid and relevant—as was the case in Egyptian Goddess, there might still be similarities although the theoretical framework and thus the purpose of looking at the prior art is different.

Then in a lengthy footnote 8 the Columbia II panel attempts to explain away a prior precedential case that reached a seemingly contrary outcome, Lanard Toys Ltd. v. Dolgencorp LLC, 958 F.3d 1337 (Fed. Cir. 2020).  If an attorney submitted a brief written in such a manner, she would at a minimum probably be harshly scolded by the presiding judge(s), and at worst be sanctioned.  But apparently this Federal Circuit panel (Judges Prost, Reyna, and Hughes) has no qualms about doing this themselves.  It is possible to argue that the Columbia II decision, although designated as precedential by the panel, is actually non-precedential due to being in conflict with Lanard ToysSee Newell Cos., Inc. v. Kenney Mfg. Co., 864 F.2d 757, 765 (Fed. Cir. 1988) (when Fed. Cir. panel decisions are in conflict, the later one is non-precedential).

In any event, one issue that footnote 8 of Columbia II does not fully address is the question of comparison art when the claimed article is specifically a simulation, and to the extent that it does that footnote may not be controlling.  MPEP § 1504.01(d) (9th Ed., Rev. 07.2022, Feb. 2023) deals designs attempting to claim articles that are simulations of something else.  The Columbia case does not specifically address In re Wise, 340 F.2d 982, 144 USPQ 354 (CCPA 1965), which dealt with the use of something other than the same article as prior art to affirm a rejection of a claimed design.  There, the claimed design was a “promotional advertising souvenir”, whereas one of the prior art references was a mere “representation of a conventionalized teardrop.”  Id. at 982-83.  In particular, the claimed design showed a teardrop shape article that was hollow with transparent walls, within which appears a planar member shown in dotted lines, on which advertising matter is to be placed, and additional prior art was cited for the proposition that display devices inside of hollow transparent containers were known—the fact that the interior components were in broken lines meant that their specific content carried no patentable weight.  Id. at 983-84.  Partly the issue raised here is whether Wise was—or could be—abrogated by In re Surgisil, L.L.P., 14 F.4th 1380 (Fed. Cir. 2021), which did not specifically address Wise or a “simulation”-based rejection, or other seemingly contrary precedent like In re Glavas, 230 F.2d 447, 450 (CCPA 1956) (“the use to which an article is to be put has no bearing on its patentability as a design and that if the prior art discloses any article of substantially the same appearance as that of an applicant, it is immaterial what the use of such article is. Accordingly, so far as anticipation by a single prior art disclosure is concerned, there can be no question as to nonanalogous art in design cases”).  Surgisil overturned a patent office rejection premised on the title of the application not limiting the scope of the claim of a pending design application, where the applied-for design was titled a “lip implant” but the cited prior art having essentially an identical shape was for an artist’s “stump” blending/smudging tool.  That result in Surgisil stands in contrast to both Glavas, which said use and non-analagous art issues are irrelevant to patentability of designs, and Wise, which cited a mere representation of a teardrop that was not, specifically, a “promotional advertising souvenir” as claimed. 

Another way to look at this is to say that footnote 8 of Columbia II is mere dicta and not binding, because Columbia II did not deal with allegations that an asserted patented design was a “simulation”.  From that perspective, the footnote 8 discussion about waiver of arguments can be disregarded (the very fact that this discussion was placed in a footnote rather than in the main text provides some support for viewing it as mere dicta).  This is significant because the Columbia II panel could not overrule Lanard Toys, and neither the Columbia II panel nor the Surgisil panel could overrule Wise or GlavasSee South Corp. v. U.S., 690 F.2d 1368, 1369 (Fed. Cir. 1982) (“the holdings of . . . the United States Court of Customs and Patent Appeals, announced . . . before the close of business September 30, 1982, shall be binding as precedent in this court.”); Newell, 864 F.2d at 765.

The Columbia II panel argues that “using the same scope for anticipatory prior art and comparison prior art makes good practical sense.”  This is asserted without addressing the (“wise”) reasoning of the Wise decision, which set out contrary practicalities when an asserted design is alleged to be a simulation.  That is, Wise pointed out that a design may not be patentable if it merely simulates a known shape from another context, and a patentee cannot obtain exclusive rights by merely reproducing essentially generic representations—a concern that in many ways mirrors cases about utility patent eligibility where results are recited coupled with only generic or conventional computerization hardware.  Cf., e.g., Elec. Power Group, LLC v. Alstom SA, 830 F.3d 1350 (Fed. Cir. 2016) (claims were patent-ineligible abstract ideas because they did not require “use of anything but entirely conventional, generic technology.”). 

Other areas that remain somewhat unresolved pertain to partial claims, multi-part articles, and language reflecting intended use. For instance, if a design patent is for a “motorcycle with windscreen,” is prior art to a motorcycle alone (without a windscreen) available as comparison art, or prior art to a windscreen in isolation? Or a combination of both motorcycle and windshield comparison references? Does the answer depend at all on whether or not broken lines are used in the patent to make a partial claim? There a risk that design patents could gain inappropriate coverage over combinations of known (useful) elements in their functional capacity if and when the only available prior art shows merely some but not all of the components together in a single reference. And what about mere intended use language in the title of the patent? If the claim is to a “cat toy” and the prior art was expressly marketed as a “dog toy”, can the dog toy be used as comparison art, when both cats and dogs could actually play with either toy? Both instances involve a toy (and an animal toy no less), and differ only in the intended use by a different animal. There is older precedent stating that “the use to which an article is to be put has no bearing on its patentability as a design and that if the prior art discloses any article of substantially the same appearance as that of an applicant, it is immaterial what the use of such article is.” Glavas, 230 F.2d at 450.

These sorts of questions put added emphasis on the still-ambiguous role of claim construction in design patent litigation, as well as the need to carefully sect a title for a new design patent application. Parties to litigation now have added incentive to argue about claim construction in design patent cases, because the proper construction will determine not only the scope of the claim but also the availability of comparison prior art.

October 2023
Photo of Austen Zuege

Austen Zuege is an attorney at law and registered U.S. patent attorney in Minneapolis whose practice encompasses patents, trademarks, copyrights, domain name cybersquatting, IP agreements and licensing, freedom-to-operate studies, client counseling, and IP litigation. If you have patent, trademark, or other IP issues, he can help.